Related Experiment Video

Updated: May 14, 2025

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.0K

Four-year recurrence-free survival in metastatic uterine adenosarcoma with somatic BRCA2 mutation on olaparib

Katie Foug1, Stephanie L Skala2, Erica Stien3

  • 1University of Michigan, School of Medicine, Ann Arbor, MI, United States.

Gynecologic Oncology Reports
|April 11, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
PARP inhibitorRecurrent diseaseSomatic BRCA mutationUterine adenosarcoma

More Related Videos

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Related Experiment Videos

Last Updated: May 14, 2025

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.0K
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

308
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
308
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

Articles linked to this work by shared authors, journal, and citation graph.

Direct to Radiology Emergency Avoidance Management (DREAM): A Quality Improvement Research Study on Reducing Emergency Department Overcrowding.

Joint Commission journal on quality and patient safety·2026

The new (version 9) American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging protocol for carcinoma of the vulva.

CA: a cancer journal for clinicians·2026

A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumor.

Gynecologic oncology·2026

Metastatic High-Grade Endometrioid Carcinoma to the Lung With Pilomatrix Carcinoma-Like Morphology: Potential for Misdiagnosis as Non-Small Cell Carcinoma.

The American journal of surgical pathology·2026

Anti-CAR Immunity Drives Acquired Therapeutic Resistance to GD2-CAR T Cell Therapy in Diffuse Midline Glioma.

medRxiv : the preprint server for health sciences·2026

Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

JCO precision oncology·2026

Barriers to the recognition and evaluation of abnormal uterine bleeding among individuals at increased risk for endometrial Cancer.

Gynecologic oncology reports·2026

Stevens-Johnson syndrome precipitating days after treatment for dostarlimab-induced autoimmune encephalitis: a case report.

Gynecologic oncology reports·2026

Advances in uterine sarcoma management: A mini-review of clinical practice and molecular insights.

Gynecologic oncology reports·2026

Docetaxel for recurrent adult granulosa cell tumor enabling tertiary cytoreduction.

Gynecologic oncology reports·2026

AfroSHARE Summit: visions of health equity for black women with gynecologic and breast cancers.

Gynecologic oncology reports·2026

Successful treatment of recurrent epithelioid trophoblastic tumor (ETT) with pembrolizumab after pembrolizumab: A case report and review of literature in treatment of ETT.

Gynecologic oncology reports·2026

Multi-omics integration identifies Acsm2/ACSM2A deficiency as a metabolic driver of ZBP1-mediated PANoptosis in acute kidney injury.

Frontiers in cell and developmental biology·2026

HER2 amplification as a resistance mechanism to osimertinib and its successful treatment with trastuzumab deruxtecan: a case report.

Frontiers in oncology·2026

Targeting Tumor-derived Sphingosine Kinase 2 Unleashes Antitumor Immunity and Improves Survival of Mice with Group 3 Medulloblastoma.

bioRxiv : the preprint server for biology·2026

Direct Coronary Vascular and Lipidomic Remodeling by Low-Dose GLP-1 Agonist Therapy in Cardiometabolic HFpEF.

Research square·2026

From Computational Prediction to In Vivo Experimental Validation: A Translational AI Pipeline for Anthracycline-Induced Cardiotoxicity.

Research square·2026

LncRNA-mediated organization of oncogenic chromatin state is a targetable vulnerability in leukemia.

bioRxiv : the preprint server for biology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us